Oxford BioMedica (GB:OXB) has released an update.
Oxford Biomedica, a leading cell and gene therapy CDMO, has announced that its total number of voting rights has reached 105,341,569 as of the end of August 2024, with all shares in circulation and none held in treasury. This key figure is crucial for shareholders who need to disclose changes in their stakes as per regulatory requirements. The company continues to innovate in viral vector development and manufacturing, serving clients globally and operating out of facilities in the UK, France, and the US.
For further insights into GB:OXB stock, check out TipRanks’ Stock Analysis page.
